Drug intelligence / Profile preview

transferrin

Development stage: Preclinical
Lead developer: New York Blood Center
Modality: Recombinant Proteins and Enzymes
Administration: Oral, Intranasal, Intraductal, Intravenous

Overview

Transferrin is a naturally occurring glycoprotein that serves as the primary iron transport protein in the bloodstream, delivering iron to various tissues. It is currently under investigation as a potential therapeutic agent for iron overload anemias, such as Sickle Cell Anemia and Beta-Thalassemia. Research indicates that exogenous transferrin administration can reverse iron overload by binding free iron, thereby reducing oxidative stress, and can improve anemia by modulating iron availability for erythropoiesis.

Targets

TFRC (Transferrin Receptor)Fe3+ (Ferric iron)

Beyond the preview

Go deeper on transferrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on transferrin.

Explore the full profile